Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS) presented preliminary data from the ARC-8 Phase 1/1b study at ASCO 2021, focusing on the safety and efficacy of AB680, a small-molecule CD73 inhibitor, in metastatic pancreatic cancer. The study involved 19 patients receiving AB680, nab-paclitaxel, and gemcitabine. No significant additive toxicity was observed, although one patient experienced Grade 2 autoimmune hepatitis. Preliminary efficacy showed that 88% of patients had lesion shrinkage, with an overall response rate of 41%. AB680 was selected for expansion at 100mg every two weeks, showing potential for advancing treatment in this challenging cancer type.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options for 31,600 shares to three new employees, priced at $30.83 each, reflecting the company's closing share price on January 8, 2021. This initiative is part of the Company’s 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies, with four clinical candidates under evaluation for various cancer types, including the dual A2a/A2b antagonist, Etrumadenant, currently in multiple Phase 2 and 1b studies.
Arcus Biosciences (NYSE:RCUS) announced promising preliminary data from its ongoing Phase 1/1b trial, ARC-8, evaluating AB680 combined with zimberelimab and chemotherapy for front-line treatment of metastatic pancreatic cancer. The data shows favorable safety and clinical activity, indicating it is well-tolerated with side effects similar to established therapies. The company plans to present detailed results at the ASCO GI symposium on January 15, 2021, and advance to the Phase 1b expansion of the study.
Arcus Biosciences (NYSE:RCUS) announced the appointment of Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. to its Board of Directors, focusing on strengthening its leadership as it approaches a pivotal year with key clinical trials. Dr. Perlman, an experienced biotechnology leader, has played significant roles at Genentech and Tularik, while Dr. Quigley has a strong background in oncology drug discovery from Gilead and Bristol-Myers Squibb. Their expertise aims to enhance Arcus's strategy to maximize long-term value for patients and shareholders.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to 20 new employees, totaling 310,500 shares at an exercise price of $29.93. This grant adheres to the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in compliance with NYSE rules. The company is focused on developing advanced therapies for cancer, with four clinical candidates currently under investigation. Etrumadenant, AB680, Domvanalimab, and Zimberelimab represent their innovative approach to addressing unmet medical needs in oncology.
Arcus Biosciences (RCUS) and WuXi Biologics have expanded their strategic partnership to discover anti-CD39 antibodies using WuXi's proprietary technology. This collaboration marks the fourth antibody development program between the two companies. Arcus has exclusive global rights to these antibodies and will handle further development and commercialization. The CD39 axis is critical for tumor immunosuppression, and preclinical data suggest that inhibiting CD39 may enhance anti-tumor immunity. Financial details of the agreement were not disclosed, and no material impact on Arcus’s financial position is anticipated.
Arcus Biosciences (NYSE:RCUS) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 10:30 a.m. Eastern Time. The event will feature a live audio webcast accessible via the Arcus website, with a replay available for two weeks post-event.
The company focuses on oncology and is advancing four clinical candidates: Etrumadenant (AB928), AB680, Domvanalimab (AB154), and Zimberelimab (AB122), targeting significant unmet needs in various cancers.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to ten new employees, totaling 343,000 shares at an exercise price of $21.53, the closing price on November 9, 2020. This grant was made under the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in line with NYSE rules. Arcus is focused on developing innovative cancer therapies and currently has four clinical candidates: Etrumadenant, AB680, Domvanalimab, and Zimberelimab, addressing significant cancer treatment gaps.
Arcus Biosciences (NYSE:RCUS) reported Q3 2020 financial results, revealing revenues of $64.5 million, a substantial increase from $1.8 million in Q3 2019, driven by collaboration with Gilead. The company holds $785 million in cash, expected to fund operations into 2023. R&D expenses grew to $51.8 million from $17.2 million due to increased clinical trial activities. Arcus anticipates significant clinical readouts in 2021, aiming for pivotal trials for its cancer therapies, including zimberelimab and domvanalimab.
Arcus Biosciences (NYSE:RCUS) has partnered with AstraZeneca to evaluate the investigational anti-TIGIT antibody, domvanalimab, in a Phase 3 clinical trial for unresectable Stage III non-small cell lung cancer (NSCLC), using Imfinzi as a combination therapy. The collaboration aims to enhance efficacy and long-term survival rates in NSCLC patients, building on promising data from previous trials. AstraZeneca will lead the trial while both companies share costs and maintain rights to their respective therapies.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
